ArticleApplied microbiology and biotechnology2026
Effects of sialylated oligosaccharides on the N- and O-glycosylation of etanercept in recombinant CHO cells.
Article in Applied microbiology and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
In mammalian cell-based bioprocesses, glycosylation of recombinant therapeutic proteins requires stringent control and monitoring as it may affect therapeutic efficacy and safety. The sialylation of glycosylated moieties plays an important role in determining the in vivo clearance of therapeutic proteins by extending their serum half-life. In this study, six enzymatically synthesized oligosaccharides (3'-sialyllactose, 6'-sialyllactose, sialyllacto-N-tetraose a, disialyllacto-N-neotetraose, lacto-N-tetraose, and lacto-N-neotetraose) and lactose were evaluated for their effectiveness on the N- and O-glycan profiles of etanercept, a therapeutic Fc-fusion glycoprotein consisting of 3 N- and 13 O-glycosylation sites, produced in recombinant Chinese hamster ovary (rCHO) cells. Of these seven compounds, only sialylated oligosaccharide supplementation increased the proportion of the acidic isoforms, di-sialylated N-glycan and di-sialylated O-glycan, as well as the total sialic acid content of etanercept, although the degree of the effect varied. Increased sialylation resulted from increased concentrations of intracellular CMP-sialic acid, with the highest increase observed for disialyllacto-N-neotetraose, which contains the most di-sialic acid residues. In contrast, four sialylated oligosaccharides did not enhance the sialylation of etanercept produced by human embryonic kidney 293 (HEK293) cells. Taken together, enzymatically synthesized sialylated oligosaccharides represent novel supplements to enhance the sialylation of therapeutic Fc-fusion glycoproteins in rCHO cell culture. KEY POINTS: • Sialylated oligosaccharides supplementation in rCHO cell culture increased the proportion of di-sialylated N- and O-glycans of Fc-fusion glycoprotein. • Among the sialylated oligosaccharides, disialyllacto-N-neotetraose (DSLNnT) increased intracellular CMP-SA the most in two rCHO cells. • The effect of sialylated oligosaccharides on sialylation was also evaluated in HEK293 cells; however, no significant enhancement was observed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.